$0.02
(Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-96 Mln
-
ROE
-1.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.4
-
Face value
--
-
Shares outstanding
38,438,300
7 Years Aggregate
CFO
$-391.72 Mln
EBITDA
$-419.96 Mln
Net Profit
$-516.89 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Atreca Inc. Class A (BCEL)
| -31.8 | -- | -52.6 | -92.4 | -78.9 | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Atreca Inc. Class A (BCEL)
| -83.5 | -73.6 | -81.2 | 4.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Atreca Inc. Class A (BCEL)
|
0.1 | 3.6 | 0.3 | -95.1 | -21,828.5 | -265.1 | -- | 0.3 |
| 25.6 | 2,212.9 | 174.9 | -190.4 | -118.4 | -54.6 | -- | 7.0 | |
| 2.1 | 6.0 | 0.1 | -6.2 | -15,087.2 | -15.2 | -- | 1.9 | |
| 22.9 | 71.7 | 0.0 | -24.8 | -- | -81.5 | -- | 2.1 |
Shareholding Pattern
View DetailsAbout Atreca Inc. Class A (BCEL)
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action... and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California. Read more
-
President, CEO, Director & Principal Financial Officer
Mr. John A. Orwin M.B.A.
-
President, CEO, Director & Principal Financial Officer
Mr. John A. Orwin M.B.A.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Atreca Inc. Class A (BCEL)
What is the current share price of Atreca Inc Class A (BCEL) Today?
The share price of Atreca Inc Class A (BCEL) is $0.09 (NASDAQ) as of 14-Jun-2024 15:28 EDT. Atreca Inc Class A (BCEL) has given a return of -78.91% in the last 3 years.
What is the current PB & PE ratio of Atreca Inc Class A (BCEL)?
Since, TTM earnings of Atreca Inc Class A (BCEL) is negative, P/E ratio is not available.
The P/B ratio of Atreca Inc Class A (BCEL) is 0.30 times as on 14-Jun-2024, a 94 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.35 |
0.40 |
2021 |
-1.04 |
0.73 |
2020 |
-6.89 |
2.46 |
2019 |
-6.41 |
2.31 |
2018 |
-- |
-- |
What is the 52 Week High and Low of Atreca Inc Class A (BCEL)?
The 52-week high and low of Atreca Inc Class A (BCEL) are Rs -- and Rs -- as of 29-Aug-2026.
What is the market cap of Atreca Inc Class A (BCEL)?
Atreca Inc Class A (BCEL) has a market capitalisation of $ 4 Mln as on 14-Jun-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Atreca Inc Class A (BCEL)?
Before investing in Atreca Inc Class A (BCEL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.